欧洲泌尿外科学会指南更新:肾细胞癌辅助免疫检查点抑制剂及后续治疗的应用
基于KEYNOTE-564试验显示帕博利珠单抗辅助治疗显著改善高危局限性透明细胞肾细胞癌的无病生存期和总生存期(HR 0.62,95%CI 0.44-0.87;p=0.005),欧洲泌尿外科学会肾癌指南小组重新评估后强烈推荐辅助帕博利珠单抗;对于辅助帕博利珠单抗期间或之后短期复发者,不推荐免疫检查点抑制剂单药或联合治疗。
要点
- 辅助帕博利珠单抗显著改善高危局限性透明细胞肾细胞癌的总生存期(HR 0.62,95%CI 0.44-0.87;p=0.005)。
- EAU肾癌指南小组强烈推荐辅助帕博利珠单抗用于中危或高危肾癌术后患者。
- 辅助帕博利珠单抗期间或短期复发者,不推荐免疫检查点抑制剂单药或联合治疗。
核心结论
- EAU肾癌指南小组基于新试验结果更新推荐,现强烈推荐辅助帕博利珠单抗。
- 在辅助帕博利珠单抗期间或之后短期复发的患者中,不推荐免疫检查点抑制剂单药或联合治疗。
研究设计与样本
- 欧洲泌尿外科学会(EAU)肾癌指南小组重新评估KEYNOTE-564、TiNivo和CONTACT-03试验结果后更新推荐。
主要发现
- KEYNOTE-564显示辅助帕博利珠单抗显著改善高危局限性透明细胞肾细胞癌的无病生存期和总生存期。
- 辅助帕博利珠单抗显著改善总生存期(HR 0.62,95%CI 0.44-0.87;p=0.005)。
- 转移性背景下ICI治疗后进展的后续治疗试验(TiNivo和CONTACT-03)不支持ICI单药或联合治疗用于辅助ICI治疗期间或之后复发的患者。
- 辅助帕博利珠单抗治疗失败后尚无前瞻性试验结果。
关键数值与推荐
- EAU肾癌指南小组强烈推荐辅助帕博利珠单抗。
- 不推荐ICI单药或联合治疗用于辅助帕博利珠单抗期间或短期复发患者。
临床怎么用
- 中危或高危肾癌术后患者强烈推荐接受帕博利珠单抗辅助治疗。
- 需与患者讨论相当比例患者会出现改变生活或严重的副作用。
局限性
- 辅助帕博利珠单抗治疗失败后尚无前瞻性试验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The KEYNOTE-564 trial showed that adjuvant immune checkpoint inhibitor (ICI) therapy with pembrolizumab, a PD-1 antibody, significantly improved disease-free survival (DFS) and overall (OS) survival in localised clear-cell renal cell carcinoma (RCC) with a high risk of relapse. The TiNivo and CONTACT-03 trials have reported results for subsequent therapy after progression on ICI therapy in the metastatic setting. The European Association of Urology (EAU) RCC guidelines panel reassessed the new trial results to update recommendations for adjuvant therapy and post-adjuvant therapy. Adjuvant pembrolizumab significantly improved OS (hazard ratio 0.62, 95% confidence interval 0.44-0.87; p = 0.005). Recent trials of subsequent ICI after recurrence on ICI in the metastatic setting do not support ICI monotherapy or combination therapy in patients with recurrence on or after adjuvant ICI therapy. There are no prospective trial results for treatment after adjuvant pembrolizumab failure. On the basis of the recent results, the EAU RCC guidelines panel has updated the recommendation for adjuvant therapy and now issues a strong recommendation for adjuvant pembrolizumab. ICI monotherapy or combination therapy is not recommended in patients with recurrence during or shortly after adjuvant pembrolizumab. PATIENT SUMMARY: Treatment with an immunotherapy drug called pembrolizumab after surgery in patients with intermediate-risk or high-risk kidney cancer delays the time to recurrence of cancer and prolongs survival. Therefore, pembrolizumab after surgery is strongly recommended for these patients. However, a significant proportion of patients have life-changing or serious side effects and these must be discussed.
引用
- Bedke J, Ghanem YA, Albiges L, et al. Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma. Eur Urol. 2025. PMID: 39904712. doi:10.1016/j.eururo.2025.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。